Carl von Halem
CIK: 0002146823
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
VRXA
Veraxa Biotech AG - Post de-SPAC
Officer
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About von Halem Carl
von Halem Carl (SEC CIK 0002146823) files insider reports with the SEC as Interim CFO of Veraxa Biotech AG - Post de-SPAC (VRXA).
Signal8 holds 1 ownership filing by von Halem Carl, a Form 3, filed on Aug 20, 2026. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on von Halem Carl's filings is in ZURICH.
Other insiders filing for Veraxa Biotech AG - Post de-SPAC (VRXA)
- Gruninger Marc, Director
- Ziegler Christoph Samuel, Director
- Hosseinion Warren, Director
- Willener Raju Sudir, Chief Financial Officer
- Baumann Oliver Rolf, Director
- Antz Christoph Rudiger, Chief Executive Officer